Kyntra Bio Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
KYNB
- Share Price
-
$1.59
- (As of Friday Closing)
Kyntra Bio General Information
Description
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Contact Information
Website
www.kyntrabio.comCorporate Office
- 350 Bay Street
- Suite 100 Number 6009
- San Francisco, CA 94133
- United States
Corporate Office
- 350 Bay Street
- Suite 100 Number 6009
- San Francisco, CA 94133
- United States
Kyntra Bio Timeline
Kyntra Bio Stock Performance
As of 20-Nov-2026, Kyntra Bio’s stock price is $1.59. Its current market cap is $6.32M with 4.05M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.59 | $1.83 | $1.56 - $10.47 | $6.32M | 4.05M | 30.2K | -$4.27 |
Kyntra Bio Financials Summary
As of 30-Sep-2026, Kyntra Bio has a trailing 12-month revenue of $5.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (42,391) | (47,943) | 43,659 | 91,471 |
| Revenue | 5,303 | 6,440 | 29,621 | 46,803 |
| EBITDA | (12,791) | (51,730) | (147,724) | (312,791) |
| Net Income | (17,287) | 183,452 | (47,579) | (284,232) |
| Total Assets | 48,851 | 119,594 | 214,525 | 423,529 |
| Total Debt | 0 | 0 | 73,092 | 149,614 |
Kyntra Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kyntra Bio Comparisons
Industry
Financing
Details
Kyntra Bio Competitors (40)
One of Kyntra Bio’s 40 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Kyntra Bio Patents
Kyntra Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024383235-A1 | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) | Pending | 22-Nov-2023 | ||
| WO-2025111214-A1 | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) | Inactive | 22-Nov-2023 | ||
| WO-2024238207-A1 | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (cia) | Inactive | 17-May-2023 | ||
| WO-2024226713-A2 | Solid [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino] acetic acid | Inactive | 28-Apr-2023 | ||
| WO-2024226713-A3 | Solid [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino] acetic acid | Inactive | 28-Apr-2023 | A61K9/2018 |
Kyntra Bio Signals
Kyntra Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Kyntra Bio FAQs
-
When was Kyntra Bio founded?
Kyntra Bio was founded in 1993.
-
Where is Kyntra Bio headquartered?
Kyntra Bio is headquartered in San Francisco, CA.
-
What is the size of Kyntra Bio?
Kyntra Bio has 34 total employees.
-
What industry is Kyntra Bio in?
Kyntra Bio’s primary industry is Drug Discovery.
-
Is Kyntra Bio a private or public company?
Kyntra Bio is a Public company.
-
What is Kyntra Bio’s stock symbol?
The ticker symbol for Kyntra Bio is KYNB.
-
What is the current stock price of Kyntra Bio?
As of 20-Nov-2026 the stock price of Kyntra Bio is $1.59.
-
What is the current market cap of Kyntra Bio?
The current market capitalization of Kyntra Bio is $6.32M.
-
What is Kyntra Bio’s current revenue?
The trailing twelve month revenue for Kyntra Bio is $5.3M.
-
Who are Kyntra Bio’s competitors?
Pliant Therapeutics, Sarepta Therapeutics, Minerva Neurosciences, Verona Pharma, and Rein Therapeutics are some of the 40 competitors of Kyntra Bio.
-
What is Kyntra Bio’s annual earnings per share (EPS)?
Kyntra Bio’s EPS for 12 months was -$4.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process